Sandra Navarra

2.1k total citations · 1 hit paper
22 papers, 739 citations indexed

About

Sandra Navarra is a scholar working on Rheumatology, Immunology and Oncology. According to data from OpenAlex, Sandra Navarra has authored 22 papers receiving a total of 739 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Rheumatology, 6 papers in Immunology and 4 papers in Oncology. Recurrent topics in Sandra Navarra's work include Rheumatoid Arthritis Research and Therapies (7 papers), Spondyloarthritis Studies and Treatments (5 papers) and Systemic Lupus Erythematosus Research (5 papers). Sandra Navarra is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (7 papers), Spondyloarthritis Studies and Treatments (5 papers) and Systemic Lupus Erythematosus Research (5 papers). Sandra Navarra collaborates with scholars based in Philippines, United States and Netherlands. Sandra Navarra's co-authors include Cristina Arriens, Laura Lisk, Brad H. Rovin, Joshua M. Kaplan, Samir V. Parikh, Y K Onno Teng, Dawn J. Caster, Neil Solomons, Ellen M. Ginzler and Simrat Randhawa and has published in prestigious journals such as The Lancet, Annals of the Rheumatic Diseases and American Journal of Physiology-Endocrinology and Metabolism.

In The Last Decade

Sandra Navarra

20 papers receiving 724 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

2021 299 citations Brad H. Rovin, Y K Onno Teng et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandra Navarra Philippines	9	531	402	154	126	83	22	739
A. Friedman United States	9	621 1.2×	337 0.8×	102 0.7×	137 1.1×	94 1.1×	25	743
George Stojan United States	10	440 0.8×	302 0.8×	78 0.5×	59 0.5×	32 0.4×	26	653
J Gough Canada	12	717 1.4×	404 1.0×	113 0.7×	46 0.4×	54 0.7×	13	877
Damon Bass United States	14	1.1k 2.0×	753 1.9×	526 3.4×	173 1.4×	52 0.6×	28	1.4k
Henrique Ataíde Mariz Brazil	11	365 0.7×	247 0.6×	139 0.9×	88 0.7×	59 0.7×	17	695
A. Alonso-Ruiz Spain	10	439 0.8×	175 0.4×	47 0.3×	275 2.2×	66 0.8×	16	810
Kerry Gairy United Kingdom	11	249 0.5×	160 0.4×	162 1.1×	79 0.6×	22 0.3×	29	562
Deva Situnayake United Kingdom	13	575 1.1×	155 0.4×	108 0.7×	22 0.2×	123 1.5×	24	783
C. Molta United States	20	916 1.7×	888 2.2×	221 1.4×	31 0.2×	268 3.2×	36	1.3k
Laura Lisk United States	12	943 1.8×	344 0.9×	218 1.4×	759 6.0×	78 0.9×	17	1.3k

Countries citing papers authored by Sandra Navarra

Since Specialization

Citations

This map shows the geographic impact of Sandra Navarra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Navarra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Navarra more than expected).

Fields of papers citing papers by Sandra Navarra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Navarra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Navarra. The network helps show where Sandra Navarra may publish in the future.

Co-authorship network of co-authors of Sandra Navarra

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Navarra. A scholar is included among the top collaborators of Sandra Navarra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Navarra. Sandra Navarra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Werth, Victoria P., Richard Furie, Juanita Romero‐Díaz, et al.. (2025). Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary. Immunotherapy. 17(3). 161–173.

Kirkham, Bruce, Peter Nash, Dèlia Reina, et al.. (2022). Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study. Clinical and Experimental Rheumatology. 41(3). 589–596. 2 indexed citations

Rovin, Brad H., Y K Onno Teng, Ellen M. Ginzler, et al.. (2021). Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 397(10289). 2070–2080. 299 indexed citations breakdown →

Tahir, Hasan, Philip J. Mease, Robert Landewé, et al.. (2020). P250 Effect of secukinumab on radiographic progression through 2 years in patients with active PsA: end-of-study results from a Phase 3 study. Lara D. Veeken. 59(Supplement_2). 1 indexed citations

Heijde, Désirée van der, Philip J. Mease, Robert Landewé, et al.. (2019). Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Lara D. Veeken. 59(6). 1325–1334. 45 indexed citations

Heijde, D. van der, Philip J. Mease, Robert Landewé, et al.. (2018). OP0306 Subcutaneous secukinumab inhibits radiographic progression in psoriatic arthritis: analysis by prior anti-tnf therapy and concomitant methotrexate use. Annals of the Rheumatic Diseases. 77. 199–200. 1 indexed citations

Golder, Vera, Molla Huq, Kate Franklyn, et al.. (2017). Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study. Seminars in Arthritis and Rheumatism. 46(6). 798–803. 15 indexed citations

Yoo, Dae‐Hyun, Artur Racewicz, Jan Brzezicki, et al.. (2016). A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Research & Therapy. 18(1). 82–82. 137 indexed citations

Chan, Madelynn, et al.. (2016). Development and implementation of Models of Care for musculoskeletal conditions in middle-income and low-income Asian countries. Best Practice & Research Clinical Rheumatology. 30(3). 398–419. 13 indexed citations

10.

Yoo, Dae‐Hyun, Artur Racewicz, Jan Brzezicki, et al.. (2013). OP0068 A Phase 3 Randomised Controlled Trial to Compare CT-P13 with Infliximab in Patients with Active Rheumatoid Arthritis: 54 Week Results from the Planetra Study. Annals of the Rheumatic Diseases. 72. A73–A73. 21 indexed citations

11.

Wallace, DJ, Sandra Navarra, M. Pétri, et al.. (2012). Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 22(2). 144–154. 88 indexed citations

12.

Robinson, Don, Daniel Aguilar, Robert W. Dubois, et al.. (2010). Impact of systemic lupus erythematosus on health, family, and work: The patient perspective. Arthritis Care & Research. 62(2). 266–273. 62 indexed citations

13.

Pisera, Daniel, Marianela Candolfi, Sandra Navarra, et al.. (2004). Estrogens sensitize anterior pituitary gland to apoptosis. American Journal of Physiology-Endocrinology and Metabolism. 287(4). E767–E771. 34 indexed citations

14.

Sibert, L., et al.. (2002). [Breast metastasis of kidney cancer. Diagnostic and therapeutic features].. PubMed. 12(6). 1272–4. 3 indexed citations

15.

Mancuso, Monique, et al.. (2000). Preperitoneal, minimally invasive, prosthetic groin hernia repair. Hernia. 4(4). 316–320. 1 indexed citations

16.

Navarra, Sandra, et al.. (1999). [Malignant neuroendocrine tumor of the bladder: an entity not to be unrecognized].. PubMed. 9(1). 129–32. 4 indexed citations

17.

Navarra, Sandra, et al.. (1998). [ST52 treatment of cancer of the prostate during the hormonal resistance phase].. PubMed. 32(1). 39–44. 2 indexed citations

18.

Sessa, Edoardo, et al.. (1994). [Parietal recurrence after resection of colorectal carcinoma].. PubMed. 65(2). 233–7. 1 indexed citations

19.

Micheletti, Gabriele, et al.. (1993). [Hypocobaltemia in chronic obstructive arteriopathy. Physiopathologic and therapeutic importance].. PubMed. 48(3-4). 147–52.

20.

Navarra, Sandra, et al.. (1983). [Acute cholecystitis. Immediate or postponed treatment?].. PubMed. 38(19). 1391–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact